Bristol Myers Squibb (NYSE: BMY) saw its sales drop by 3% during the third quarter of 2022.
The US drugmaker’s revenue for the quarter totalled $11.2 billion, with the firm blaming the decline on the loss of exclusivity of end-of-patent products - particularly the multiple myeloma drug Revlimid (lenalidomide).
But analysts had in fact expected the sales total to be lower, at around $11.1 billion, according to Refinitiv data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze